Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

What Is HER2-Positive Colon Cancer? How Is It Treated?

What Is HER2-Positive Colon Cancer? How Is It Treated?

HER2 is a protein receptor on the cell surface and a mediator of cell growth signals. It is encoded by the HER2 gene. The HER2 gene is a proto-oncogene, also known as Erbb2 or ERBB2.

HER2-related alterations are known to play a driving role in various cancers. This gene and receptor are among the most extensively studied molecular targets in cancer to date. 

In HER2 + tumors, cancer cells produce too much of this receptor, leading to more aggressive cancer behavior. Before HER2 receptor-targeting new-generation targeted drugs were developed, HER2 positivity was associated with a poor disease course and more frequent recurrence. Approximately 20% of breast cancers are HER2-positive.

HER2 positivity is not a single phenomenon; it may involve overexpression, amplification or mutation. Overproduction of the HER2 gene (overexpression) or increased gene copies (amplification) is an important biomarker, particularly in breast cancer. Many HER2-targeted drugs are currently used, mainly in breast cancer and then in stomach cancer. However, studies show that mutations in the HER2 gene are molecular alterations as noteworthy and targetable as overproduction or amplification. All 3 changes in the HER2 gene—overexpression, amplification or mutation—can stimulate cell growth and proliferation; nevertheless, the 3 different conditions require different inhibitory drugs.

Frequency of HER2 receptor alterations in different cancer types

Targeting HER2 in Colon and Rectal Cancers

HER2 is generally overexpressed on the cell surface in colorectal cancers in approximately 3-5% of cases and in RAS/BRAF-wild-type (without mutations) colorectal tumors in 5-14% of cases. Treatment approaches for tumors with HER2 overexpression include trastuzumab plus lapatinib and trastuzumab plus pertuzumab.

In a phase 2 clinical trial, 27 heavily pretreated patients with HER2-positive metastatic colon cancer responded well to a dual targeted-drug regimen containing no chemotherapy, commonly used to treat HER2-positive breast cancer. The 27 patients included in this study were identified by screening for KRAS exon 2 (codon 12 and 13) mutation-negative metastatic colorectal cancer among 914 patients.

Most patients had extensive metastatic disease and distal (end-section) colon tumors. Nearly 75% had previously received at least four lines of treatment, and the median total duration of prior treatments was around 20 months.

Study Results

  • Patients were treated with a combination of trastuzumab and lapatinib.
  • At 1 year, 12 of 27 patients (45%) were still alive.
  • At a median follow-up of 94 weeks, one patient (4%) had a complete response, seven (26%) had a partial response, and disease stabilized in 12 patients (44%).

Conclusion

Patients with advanced colorectal cancer should also be tested for HER2 overexpression, because HER2 is a molecular target that should not be overlooked in colorectal cancers, and the currently available HER2-targeted drugs appear effective in this tumor type.

Sources

1. Harrison P. HER2 Therapy in Advanced Colorectal Cancer: 'Extraordinary'. Medscape Medical News. Available at http://www.medscape.com May 7, 2016.

2. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Apr 20.

3. André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013. 9:261-269.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

What Is HER2-Positive Colon Cancer? How Is It Treated?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy